27.5.2005

Official Journal of the European Union

C 130/1

Euro exchange rates (1)

26 May 2005

(2005/C 130/01)

1 euro=

	Currency	Exchange rate
USD	US dollar	1,2523
JPY	Japanese yen	135,58
DKK	Danish krone	7,4438
GBP	Pound sterling	0,6874
SEK	Swedish krona	9,2
CHF	Swiss franc	1,5472
ISK	Iceland króna	81,02
NOK	Norwegian krone	8,009
BGN	Bulgarian lev	1,9559
CYP	Cyprus pound	0,5764
CZK	Czech koruna	30,495
EEK	Estonian kroon	15,6466
HUF	Hungarian forint	254,26
LTL	Lithuanian litas	3,4528
LVL	Latvian lats	0,6959
MTL	Maltese lira	0,4293
PLN	Polish zloty	4,1775
ROL	Romanian leu	36 144
SIT	Slovenian tolar	239,52
SKK	Slovak koruna	39,21
TRY	Turkish lira	1,7358
AUD	Australian dollar	1,6473
CAD	Canadian dollar	1,5886
HKD	Hong Kong dollar	9,7439
NZD	New Zealand dollar	1,7595
SGD	Singapore dollar	2,0801
KRW	South Korean won	1 254,55
ZAR	South African rand	8,2949
CNY	Chinese yuan renminbi	10,3647
HRK	Croatian kuna	7,318
IDR	Indonesian rupiah	11 884,33
MYR	Malaysian ringgit	4,7586
PHP	Philippine peso	68,282
RUB	Russian rouble	35,18
THB	Thai baht	50,599

(1)

Source: reference exchange rate published by the ECB.

27.5.2005

Official Journal of the European Union

C 130/2

Final report of the Hearing Officer in Case COMP/37.214 — DFB Joint Selling of Media Rights

(pursuant to Article 15 of Commission Decision 2001/462/EC, ECSC of 23 May 2001 on the terms of reference of Hearing Officers in certain competition proceedings — OJ L 162, 19.6.2001, p. 21)

(2005/C 130/02)

(Text with EEA relevance)

The decision concerns the central marketing of the media exploitation rights in respect of matches in the first and second national football divisions for men (Bundesliga and 2. Bundesliga) by the Liga-Fußballverband e.V. (‘League Association’) in Germany. The League association is a registered association and ordinary member of the Deutscher Fußballbund (‘DFB’ — German Football Association).

By letter of 25 August 1998, the DFB, in accordance with Articles 2 and 4 of Regulation No 17/62, applied for negative clearance or, failing this, an individual exemption under Article 81(3) of the Treaty in respect of the central marketing of television and radio broadcasting rights and any other technical forms of exploitation for matches in the first and second national football divisions for men. The League Association, which was founded in 2001 and which took over the task of marketing from the DFB, adopted the DFB's amended notification as its own on 19 February 2003.

On 9 January 1999 the Commission, in a notice published in the Official Journal of the European Communities, invited third parties to submit their observations. (1) By decision of 22 October 2003, it initiated proceedings under Article 9(3) of Regulation No 17. On 30 October 2003 it announced its intention of giving a positive assessment of the amended joint marketing arrangements in a notice published in the Official Journal of the European Union (2) and subsequently received observations from interested third parties.

With the entry into force of Council Regulation (EC) No 1/2003 on 1 May 2004, the League Association's former application for negative clearance or individual exemption lapsed in accordance with Article 34(1) of Regulation (EC) No 1/2003.

However, in accordance with Article 34(2) of Regulation (EC) No 1/2003, the initiation of proceedings under Article 9(3) of Regulation No 17 which corresponds to that under Article 2(1) of Implementing Regulation (EC) No 773/2004, continued to have effect.

Accordingly, with effect from 1 May 2004, the Commission, acting on its own initiative, continued with the proceedings with a view to adopting a decision under Chapter III of Regulation (EC) No 1/2003.

On 18 June 2004 the Commission issued a preliminary assessment in accordance with Article 9(1) of Regulation (EC) No 1/2003 that was addressed to the League Association and made available to the DFB.

By letter of 6 August 2004, the League Association submitted amended undertakings in respect of the central marketing arrangements as commitments within the meaning of Article 9(1) of Regulation (EC) No 1/2003.

On 14 September 2004 the Commission, in a notice published pursuant to Article 27(4) of Regulation (EC) No 1/2003 in the Official Journal of the European Union, invited interested third parties to submit observations on the proposed commitments within one month of the publication of the notice. These observations were transmitted to the League Association.

In light of the commitments offered by the League Association, the Commission considers that there are no longer grounds for action by the Commission and, without prejudice to Article 9(2) of Regulation (EC) No 1/2003, the proceedings in the present case shall be brought to an end.

No queries were raised before the Hearing Officer by the League Association or other companies as to the market test. No requests for additional information were made. The League Association has informed the Commission that the information necessary to assess the case was at its disposal.

In the light of the above, the case does not call for any particular comments as regards the right to be heard.

Brussels, 7 December 2004.

Serge DURANDE

(1) OJ C 6, 9.1.1999, p. 10.

(2) OJ C 261, 30.10.2003, p. 13.

27.5.2005

Official Journal of the European Union

C 130/4

Opinion of the Advisory Committee on restrictive practices and dominant positions given at its 386th meeting on 6 December 2004 concerning a preliminary draft decision in Case COMP/A.37.214 — DFB

(2005/C 130/03)

(Text with EEA relevance)

The majority of the Advisory Committee agrees that the joint selling of the media rights by the German Bundesliga raises competition concerns under Article 81(1) and the proceedings in this case can be concluded by means of a decision pursuant to Article 9 of Council Regulation (EC) No 1/2003. A minority voted against. A minority abstains.

The majority of the Advisory Committee agrees with the European Commission that the league Association's commitments introduce competition in the marketing of Bundesliga and 2. Bundesliga rights between the league and the clubs and allow for new in particular club branded products, reduce the scope and duration of future marketing deals and provide a transparent and non-discriminatory procedure, and improve accessibility of content for TV, Radio and the new media operators. A minority voted against. A minority abstains.

The majority of the Advisory Committee agrees with the European Commission that — in light of the commitments offered by the Undertaking — there are no longer grounds for action by the Commission, without prejudice to Article 9(2) of Council Regulation (EC) No 1/2003. A minority voted against. A minority abstains.

4.	The majority of the Advisory Committee agrees with the European Commission that these commitments shall be binding on the League Association until 30 June 2009. A minority voted against. A minority abstains.

5.	The Advisory Committee recommends the publication of its opinion in the Official Journal of the European Union.

6.	The Advisory Committee asks the Commission to take into account all the other points raised during the discussion.

27.5.2005

Official Journal of the European Union

C 130/5

Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 April 2005 to 15 May 2005

(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93) (1)

(2005/C 130/04)

— Modification of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93): Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
20.4.2005	Velcade	Janssen-Cilag International NV, Turnhoutseweg, 30 — B-2340 Beerse	EU/1/04/274/001	22.4.2005
20.4.2005	Viramune	Boehringer Ingelheim International GmbH, Binger Strasse 173 — D-55216 Ingelheim am Rhein	EU/1/97/055/001-002	22.4.2005
20.4.2005	Paxene	Norton Healthcare Limited, Albert Basin, Royal Docks, London E16 2QJ, United Kingdom	EU/1/99/113/001-004	22.4.2005
25.4.2005	Zeffix	Glaxo Group Ltd, Greenford, Middlesex UB6 0NN, United Kingdom	EU/1/99/114/001-003	27.4.2005
25.4.2005	HBVAXPRO	Sanofi Pasteur MSD, SNC, 8, rue Jonas Salk, F-69007 Lyon	EU/1/01/183/001-019	27.4.2005
25.4.2005	Humira	Abbott Laboratories Ltd, Queenborough, Kent ME11 5EL, United Kingdom	EU/1/03/256/001-006	27.4.2005
25.4.2005	GONAL f	Serono Europe Limited, 56, Marsh Wall, London E14 9TP, United Kingdom	EU/1/95/001/001-035	27.4.2005
25.4.2005	Trudexa	Abbott Laboratories Ltd, Queenborough, Kent ME11 5EL, United Kingdom	EU/1/03/257/001-006	27.4.2005
27.4.2005	Viagra	Pfizer Limited, Sandwich, Kent CT13 9NJ, United Kingdom	EU/1/98/077/001-012	29.4.2005
27.4.2005	Keppra	UCB SA, Allée de la recherche, 60, B-1070 Bruxelles Researchdreef, 60, B-1070 Brussel	EU/1/00/146/001-027	29.4.2005
27.4.2005	Lantus	Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main	EU/1/00/134/012	29.4.2005
27.4.2005	Optisulin	Aventis Pharma Deutschland GmbH, D-65926 Frankfurt am Main	EU/1/00/133/008	29.4.2005
27.4.2005	Forsteo	Eli Lilly Nederland BV, Grootslag 1-5, 3991 RA Houten, Nederland	EU/1/03/247/001-002	29.4.2005
27.4.2005	Neupopeg	Dompé Biotec SpA, Via San Martino, 12, I-20122 Milano	EU/1/02/228/001-002	29.4.2005
27.4.2005	Cellcept	Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom	EU/1/96/005/001-006	29.4.2005
27.4.2005	Carbaglu	Orphan Europe, Immeuble ‘Le Guillaumet’, F-92046 Paris La Défense	EU/1/02/246/001-003	29.4.2005
28.4.2005	Herceptin	Roche Registration Limited, 40 Broadwater Road, Welwyn Garden City, Hertfordshire AL7 3AY, United Kingdom	EU/1/00/145/001	3.5.2005
28.4.2005	Emend	Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom	EU/1/03/262/001-006	3.5.2005
28.4.2005	Emend	Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom	EU/1/03/262/001-006	3.5.2005
28.4.2005	Enbrel	Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom	EU/1/99/126/006-011	3.5.2005
28.4.2005	Rapamune	Wyeth Europa Limited, Huntercombe Lane South, Taplow, Maidenhead, Berkshire, SL6 0PH, United Kingdom	EU/1/01/171/001-012	3.5.2005
29.4.2005	Neulasta	Amgen Europe BV, Minervum 7061, 4817 ZK Breda, Nederland	EU/1/02/227/001-002	3.5.2005
10.5.2005	Lyrica	Pfizer Ltd; Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom	EU/1/04/279/001-025	13.5.2005
10.5.2005	Cancidas	Merck Sharp & Dohme Ltd, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom	EU/1/01/196/001-003	13.5.2005
13.5.2005	Apidra	Aventis Pharma Deutschland GmbH, Brueningstraße 50, D-65926 Frankfurt am Main	EU/1/04/285/001-028	18.5.2005

— Withdrawal of a marketing authorisation (Article 12 of Council Regulation (EEC) No 2309/93)

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
25.4.2005	Infanrix Hep B	GlaxoSmithKline Biologicals SA, rue de l'Institut 89, B-1330 Rixensart	EU/1/97/048/001-014	27.4.2005

— Modification of a marketing authorisation (Article 34 of Council Regulation (EEC) No 2309/93): Accepted

Date of the decision	Name of the medicinal product	Holder of the marketing authorisation	Number of the entry in the Community Register	Date of notification
18.4.2005	Bayovac CSF E2	Pfizer Limited, Sandwich, Kent, CT13 9NJ, United Kingdom Bayer AG, Geschäftsbereich Tiergesundheit, D-51368 Leverkusen	EU/2/00/025/001-004	20.4.2005
21.4.2005	Eurifel FeLV	Merial, 29 Avenue Tony Garnier, F-69007 Lyon	EU/2/00/019/001-003	27.4.2005
27.4.2005	Ibraxion	Merial, 29 avenue Tony Garnier, F-69007 Lyon	EU/2/99/017/001-006	29.4.2005
27.4.2005	Metacam	Boehringer Ingelheim Vetmedica GmbH, D-55216 Ingelheim am Rhein	EU/2/97/004/001 EU/2/97/004/003-010	29.4.2005

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

The European Medicines Agency

7, Westferry Circus, Canary Wharf

London E14 4HB

United Kingdom

(1) OJ L 214 of 24.8.1993, p. 1.

27.5.2005

Official Journal of the European Union

C 130/8

Notice of the impending expiry of certain anti-dumping measures

(This text replaces the one published in Official Journal C 94 of 19 April 2005, p. 2.)

(2005/C 130/05)

As provided for in Article 11(2) of Council Regulation (EC) No 384/96 of 22 December 1995 (1) on protection against dumped imports from countries not members of the European Community, the Commission gives notice that, unless a review is initiated in accordance with the following procedure, the anti-dumping measures mentioned below will expire on the date mentioned in the table below.

2. Procedure

Community producers may lodge a written request for a review. This request must contain sufficient evidence that the expiry of the measures would be likely to result in a continuation or recurrence of dumping and injury.

Should the Commission decide to review the measures concerned, importers, exporters, representatives of the exporting country and Community producers will then be provided with the opportunity to amplify, rebut or comment on the matters set out in the review request.

3. Time limit

Community producers may submit a written request for a review on the above basis, to reach the European Commission, Directorate-General for Trade (Division B-1), J-79 5/16, B-1049 Brussels (2) at any time from the date of the publication of the present notice but no later than three months before the date mentioned in the table below.

4.	This notice is published in accordance with Article 11(2) of Council Regulation (EC) No 384/96 of 22 December 1995.

Product	Country(ies) of origin or exportation	Measures	Reference	Date of expiry
Coke of coal in pieces with a diameter of more than 80 mm	People's Republic of China	Anti-dumping duty	Commission Decision No 2730/2000/ECSC (OJ L 316, 15.12.2000, p. 30) (suspended by Council Regulation (EC) No 2117/2004 — OJ L 367, 14.12.2004, p. 3) as last amended by Council Regulation (EC) No 997/2004 (OJ L 183, 20.5.2004, p. 1)	16.12.2005
Polyester staple fibres	India	Anti-dumping duty	Council Regulation (EC) No 2852/2000 (OJ L 332, 28.12.2000, p. 17)	29.12.2005
Polyester staple fibres	India	Undertaking	Commission Decision No 2000/818/EC (OJ L 332, 28.12.2000, p. 116)	29.12.2005

(1) OJ L 56, 6.3.1996, p. 1. Regulation as last amended by Council Regulation (EC) No 461/2004 (OJ L 77, 13.3.2004, p. 12).

(2) Telefax : (32-2) 295 65 05.

		ISSN 1725-2423
Official Journal of the European Union		C 130

English edition	Information and Notices	Volume 48 27 May 2005

Notice No	Contents	page
	I Information
	Commission
2005/C 130/1	Euro exchange rates	1

2005/C 130/2	Final report of the Hearing Officer in Case COMP/37.214 — DFB Joint Selling of Media Rights (pursuant to Article 15 of Commission Decision 2001/462/EC, ECSC of 23 May 2001 on the terms of reference of Hearing Officers in certain competition proceedings — OJ L 162, 19.6.2001, p. 21) ( 1 )	2

2005/C 130/3	Opinion of the Advisory Committee on restrictive practices and dominant positions given at its 386th meeting on 6 December 2004 concerning a preliminary draft decision in Case COMP/A.37.214 — DFB ( 1 )	4

2005/C 130/4	Summary of Community decisions on marketing authorisations in respect of medicinal products from 15 April 2005 to 15 May 2005(Published pursuant to Article 12 or Article 34 of Council Regulation (EEC) No 2309/93)	5

2005/C 130/5	Notice of the impending expiry of certain anti-dumping measures (This text replaces the one published in Official Journal C 94 of 19 April 2005, p. 2.)	8

2005/C 130/6	Non-opposition to a notified concentration (Case COMP/M.2483 — Group Canal+/RTL/GJCD/JV) ( 1 )	9